These may include temporary skin irritation, slight redness, or increased sensitivity
What makes the triple agonist approach so compelling is how it leverages glucagon to increase energy expenditure alongside the appetite suppressing effects of GLP-1 and GIP
Target outcomes at 6 months: BFM reduced by 35 kg, SMM stable or improved, VFL reduced by 2 levels, BMR within 100 kcal of baseline, Phase Angle stable or improved
According to Mayo Clinic prescribing information, the injectable form is not intended for women who have gone through menopause, and it is not recommended for people with uncontrolled high blood pressure or certain heart and blood vessel conditions
Postoperative burr hole changes in the right frontal region
Net weight: Preservation method: Store in a cool, dry place